Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) Invested Capital (2016 - 2025)

Historic Invested Capital for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $182.7 million.

  • Assembly Biosciences' Invested Capital rose 60259.2% to $182.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 60259.2%. This contributed to the annual value of $33.4 million for FY2024, which is 1882.86% down from last year.
  • Latest data reveals that Assembly Biosciences reported Invested Capital of $182.7 million as of Q3 2025, which was up 60259.2% from $18.1 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Invested Capital registered a high of $247.2 million during Q1 2021, and its lowest value of $18.1 million during Q2 2025.
  • Over the past 5 years, Assembly Biosciences' median Invested Capital value was $70.3 million (recorded in 2023), while the average stood at $99.5 million.
  • As far as peak fluctuations go, Assembly Biosciences' Invested Capital plummeted by 5926.53% in 2023, and later soared by 60259.2% in 2025.
  • Assembly Biosciences' Invested Capital (Quarter) stood at $168.9 million in 2021, then plummeted by 51.07% to $82.7 million in 2022, then plummeted by 50.28% to $41.1 million in 2023, then fell by 18.83% to $33.4 million in 2024, then skyrocketed by 447.66% to $182.7 million in 2025.
  • Its last three reported values are $182.7 million in Q3 2025, $18.1 million for Q2 2025, and $27.1 million during Q1 2025.